Palladium Partners’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | $5.29M | Sell |
71,896
-2,815
| -4% | -$189K | 0.23% | 95 |
|
|
2021
Q4 | $4.66M | Sell |
74,711
-7,769
| -9% | -$456K | 0.19% | 97 |
|
|
2021
Q3 | $4.88M | Sell |
82,480
-72,683
| -47% | -$4.79M | 0.22% | 90 |
|
|
2021
Q2 | $10.4M | Buy |
155,163
+583
| +0.4% | +$38K | 0.49% | 55 |
|
|
2021
Q1 | $9.76M | Buy |
154,580
+2,584
| +2% | +$161K | 0.48% | 57 |
|
|
2020
Q4 | $9.43M | Buy |
151,996
+10,443
| +7% | +$642K | 0.52% | 55 |
|
|
2020
Q3 | $8.53M | Buy |
141,553
+3,355
| +2% | +$202K | 0.54% | 49 |
|
|
2020
Q2 | $8.13M | Buy |
138,198
+13,445
| +11% | +$804K | 0.56% | 53 |
|
|
2020
Q1 | $6.95M | Buy |
124,753
+75,272
| +152% | +$4.6M | 0.58% | 49 |
|
|
2019
Q4 | $3.18M | Sell |
49,481
-6,999
| -12% | -$401K | 0.2% | 100 |
|
|
2019
Q3 | $3.51M | Buy |
56,480
+3,972
| +8% | +$187K | 0.24% | 90 |
|
|
2019
Q2 | $2.38M | Buy |
52,508
+828
| +2% | +$38.6K | 0.16% | 109 |
|
|
2019
Q1 | $2.47M | Sell |
51,680
-3,235
| -6% | -$161K | 0.18% | 102 |
|
|
2018
Q4 | $2.85M | Sell |
54,915
-5,170
| -9% | -$278K | 0.23% | 89 |
|
|
2018
Q3 | $3.73M | Sell |
60,085
-1,431
| -2% | -$84.9K | 0.25% | 88 |
|
|
2018
Q2 | $3.4M | Buy |
61,516
+1,446
| +2% | +$78.1K | 0.25% | 91 |
|
|
2018
Q1 | $3.8M | Buy |
60,070
+959
| +2% | +$61.7K | 0.28% | 85 |
|
|
2017
Q4 | $3.62M | Sell |
59,111
-5,149
| -8% | -$322K | 0.26% | 90 |
|
|
2017
Q3 | $4.1M | Sell |
64,260
-1,720
| -3% | -$100K | 0.31% | 84 |
|
|
2017
Q2 | $3.68M | Buy |
65,980
+770
| +1% | +$41.9K | 0.29% | 84 |
|
|
2017
Q1 | $3.55M | Sell |
65,210
-638
| -1% | -$35K | 0.29% | 83 |
|
|
2016
Q4 | $3.85M | Buy |
65,848
+1,782
| +3% | +$97.4K | 0.32% | 80 |
|
|
2016
Q3 | $3.45M | Sell |
64,066
-1,200
| -2% | -$77.1K | 0.3% | 80 |
|
|
2016
Q2 | $4.8M | Buy |
65,266
+1,152
| +2% | +$81.4K | 0.44% | 69 |
|
|
2016
Q1 | $4.1M | Buy |
64,114
+639
| +1% | +$40.3K | 0.38% | 75 |
|
|
2015
Q4 | $4.37M | Sell |
63,475
-1,100
| -2% | -$72.7K | 0.4% | 73 |
|
|
2015
Q3 | $3.82M | Sell |
64,575
-2,757
| -4% | -$175K | 0.38% | 74 |
|
|
2015
Q2 | $4.48M | Sell |
67,332
-818
| -1% | -$53.9K | 0.4% | 74 |
|
|
2015
Q1 | $4.4M | Sell |
68,150
-50
| -0.1% | -$3.13K | 0.38% | 78 |
|
|
2014
Q4 | $4.03M | Sell |
68,200
-459
| -0.7% | -$25.9K | 0.35% | 86 |
|
|
2014
Q3 | $3.51M | Sell |
68,659
-11,512
| -14% | -$575K | 0.31% | 86 |
|
|
2014
Q2 | $3.89M | Sell |
80,171
-13,882
| -15% | -$684K | 0.35% | 83 |
|
|
2014
Q1 | $4.89M | Sell |
94,053
-3,305
| -3% | -$176K | 0.45% | 70 |
|
|
2013
Q4 | $5.17M | Sell |
97,358
-3,433
| -3% | -$175K | 0.49% | 67 |
|
|
2013
Q3 | $4.67M | Sell |
100,791
-7,500
| -7% | -$329K | 0.47% | 68 |
|
|
2013
Q2 | $4.84M | Buy |
+108,291
| New | +$4.7M | 0.51% | 61 |
|
Other funds holding BMY
Palladium Partners's BMY Position: Q1 2022 in Review
Palladium Partners reduced its Bristol-Myers Squibb (BMY) stake by 3.8% in Q1 2022, selling an estimated $189K and leaving 71,896 shares worth $5.29M. The position accounts for 0.23% of the portfolio, ranked #95.
Palladium Partners first reported a position in BMY in Q2 2013 and has held it in 36 quarters since. The position peaked at $10.4M in Q2 2021. 2,516 funds tracked by Wall St. Rank hold BMY as of Q1 2022.
- Palladium Partners held 71,896 shares of Bristol-Myers Squibb worth $5.29M as of Q1 2022.
- Palladium Partners sold 2,815 Bristol-Myers Squibb shares in Q1 2022, an estimated $189K.
- Bristol-Myers Squibb made up 0.23% of Palladium Partners's portfolio in Q1 2022, its #95 holding.
- Palladium Partners first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 36 quarters since.
- Palladium Partners's Bristol-Myers Squibb position peaked at $10.4M in Q2 2021.
- 2,516 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2022.
Based on Palladium Partners's 13F filing for Q1 2022, filed 26 Apr 2022.